Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Assoc. Prof. Dr. Feng Li | Tumor | Best Researcher Award

Qufu Normal University | China

AUTHOR PROFILE

Scopus

Google Scholar

🏫 EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Feng Li began their academic journey with a solid foundation in the life sciences, focusing on biology and computational biology during their undergraduate and graduate studies. They earned advanced degrees specializing in bioinformatics and oncology-related research, which positioned them at the intersection of biological data analysis and tumor research. Their early years were marked by exceptional performance, earning scholarships and accolades for academic excellence.

💼 PROFESSIONAL ENDEAVORS

Dr. Feng Li currently serves as an Associate Professor at Qufu Normal University in China. They have built a career that bridges teaching, research, and mentorship, shaping the next generation of scientists in the field of tumor biology and bioinformatics. They also collaborate with leading researchers and institutions, contributing to multidisciplinary projects and promoting innovation in their field.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Dr. Li’s primary research focus lies in tumor biology, particularly the application of bioinformatics to understand cancer mechanisms. Their work emphasizes:

  • Identifying biomarkers for cancer diagnostics and therapy.
  • Analyzing genomic and proteomic data to uncover tumor-related pathways.
  • Developing predictive models for patient outcomes using machine learning.

Their groundbreaking research has led to the publication of numerous peer-reviewed articles, advancing knowledge in cancer genomics and computational oncology.

🌍 IMPACT AND INFLUENCE

Through their research, Dr. Feng Li has significantly impacted the scientific community by:

  • Enhancing the understanding of cancer biology.
  • Introducing innovative bioinformatics tools for data analysis.
  • Influencing clinical practices with actionable insights from their studies.

Their work is frequently cited, reflecting their contributions to the broader academic discourse in oncology and bioinformatics.

📊 ACADEMIC CITES

Dr. Li’s publications have garnered widespread recognition, with a growing H-index reflecting their influence in the academic community. Their articles are cited by researchers worldwide, signifying the value and relevance of their findings.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Feng Li’s legacy is marked by their dedication to advancing cancer research and mentoring young scientists. Looking ahead, their focus includes:

  • Expanding research in personalized cancer therapies.
  • Fostering collaborations between bioinformatics and clinical oncology.
  • Inspiring future generations through teaching and research initiatives.

🌟 OTHER IMPORTANT TOPICS

  • Teaching Excellence: Dr. Li is recognized for their engaging teaching methods, integrating real-world research into classroom learning.
  • Community Engagement: Actively participates in academic conferences and workshops, sharing their expertise and fostering knowledge exchange.
  • Interdisciplinary Approach: Their work exemplifies how bioinformatics and oncology can converge to solve complex medical challenges.

🌟CONCLUSION 

Assoc. Prof. Dr. Feng Li has emerged as a pivotal figure in the fields of tumor biology and bioinformatics, blending academic rigor with innovative research to tackle some of the most pressing challenges in oncology. Through their groundbreaking contributions, impactful teaching, and dedication to interdisciplinary collaboration, Dr. Li has left an indelible mark on the scientific community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. SLGCN: Structure-enhanced line graph convolutional network for predicting drug–disease associations
    • Authors: Liu, B.-M., Gao, Y.-L., Li, F., Zheng, C.-H., Liu, J.-X.
    • Journal: Knowledge-Based Systems
    • Year: 2024

    2. A framework for scRNA-seq data clustering based on multi-view feature integration

    • Authors: Li, F., Liu, Y., Liu, J., Ge, D., Shang, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

    3. KFDAE: CircRNA-Disease Associations Prediction Based on Kernel Fusion and Deep Auto-Encoder

    • Authors: Kang, W.-Y., Gao, Y.-L., Wang, Y., Li, F., Liu, J.-X.
    • Journal: IEEE Journal of Biomedical and Health Informatics
    • Year: 2024

    4. Multi-Affinity network integration based on multi-omics data for tumor stratification

    • Authors: Li, F., Gao, Y., Sun, Z., Shang, J., Liu, J.-X.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2025

    5. A review: simulation tools for genome-wide interaction studies

    • Authors: Shang, J., Xu, A., Bi, M., Li, F., Liu, J.-X.
    • Journal: Briefings in Functional Genomics
    • Year: 2024

Prof. Yingfen Ying | Tumors | Women Researcher Award

Prof. Yingfen Ying | Tumors | Women Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

Scopus

PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL 👩‍⚕️🌍

EARLY ACADEMIC PURSUITS 🎓✨

Professor Yingfen Ying embarked on her academic journey with a strong focus on medical sciences, demonstrating an early aptitude for research and clinical excellence. Her academic foundation was fortified through rigorous education at Wenzhou Medical University, where she gained critical knowledge and skills that paved the way for her distinguished career. She further enriched her expertise as a visiting scholar at the University of British Columbia in Canada, a testament to her global academic vision.

PROFESSIONAL ENDEAVORS 💼🏥

Professor Ying has made significant strides as an Associate Chief Physician and master’s supervisor at Wenzhou Medical University. Her roles extend to various esteemed positions, including:

  • Member of the Obstetrics and Gynecology Rehabilitation Committee, Chinese Rehabilitation Medicine Association.
  • Vice Chairwoman of the Youth Committee, Reproductive Medicine Branch, Zhejiang Society of Traditional Chinese and Western Medicine.
  • Member of the Obstetrics and Gynecology Branch, Zhejiang Society of Translational Medicine.
    She is also affiliated with prominent international organizations, such as the American Society of Reproductive Medicine and the European Society of Human Reproduction and Embryology.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬📚

Professor Ying’s primary research interests center on the mechanistic study of environmental endocrine disruptors and reproductive endocrine diseases. Her investigations delve into the interplay between environmental factors and hormonal imbalances, significantly advancing our understanding of infertility diseases. She has led multiple national and international research projects, including those funded by the National Natural Science Foundation of China.

IMPACT AND INFLUENCE 🌟🌏

Professor Ying’s work has had far-reaching impacts in the field of reproductive medicine. She has authored nearly 30 SCI-indexed papers, contributing valuable insights and advancements to the global medical community. Her research continues to influence clinical practices and guide innovative therapeutic approaches for infertility.

ACADEMIC CITES AND PATENT ACHIEVEMENTS 📜🔑

Professor Ying’s extensive research portfolio has garnered numerous citations in high-impact journals. Additionally, she holds a European patent, exemplifying her contributions to advancing medical technology and treatment methodologies on a global scale.

LEGACY AND FUTURE CONTRIBUTIONS 🌟🚀

As a trailblazer in reproductive medicine, Professor Yingfen Ying’s legacy is defined by her commitment to advancing medical science, mentoring future generations, and improving patient outcomes. Her ongoing projects and international collaborations promise continued breakthroughs, ensuring her work remains at the forefront of reproductive health and endocrine research.

ADDITIONAL HIGHLIGHTS 🌐📖

  • Active member of youth committees in Zhejiang’s medical and scientific communities, fostering innovation and development among emerging scholars.
  • Her dedication to integrating traditional Chinese and Western medicine highlights a holistic approach to patient care and research.
  • International affiliations reflect her commitment to global medical advancements, strengthening ties between diverse medical communities.

CONCLUSION 🌟🏆

Professor Yingfen Ying exemplifies excellence in the fields of reproductive medicine and endocrine research. Her dedication to uncovering the mechanisms of infertility diseases and environmental endocrine disruptors has advanced both science and clinical practice. Through her leadership roles, impactful publications, and international collaborations, she has established herself as a global authority and advocate for holistic and innovative approaches to healthcare.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Halogen atoms determine the inhibitory potency of halogenated bisphenol A derivatives on human and rat placental 11β-hydroxysteroid dehydrogenase 2
    Authors: Shi, L., Zhang, B., Ying, Y., Ge, R.-S., Liu, Y.
    Journal: Food and Chemical Toxicology
    Year: 2023

 

  • Title: Inhibitory effects of parabens on human and rat 17β-hydroxysteroid dehydrogenase 1: Mechanisms of action and impact on hormone synthesis
    Authors: Chen, Z., Gong, C., Tang, Y., Ge, R.-S., Ying, Y.
    Journal: Toxicology
    Year: 2024

 

  • Title: Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis
    Authors: Wen, C., Chen, H., Tang, Y., Chen, C., Chen, S.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2024

 

  • Title: Leydig cell development in pubertal male rats is blocked by perfluorotetradecanoic acid through decreasing AMPK-mTOR-autophagy pathway
    Authors: Tang, Y., Shi, L., Wang, S., Ge, R.-S., Ying, Y.
    Journal: Toxicology Letters
    Year: 2023

 

  • Title: Structure-activity relationship and in silico docking analysis of dicarboximide fungicides on 17β-hydroxysteroid dehydrogenase 1 of human, rat, and pig
    Authors: Chen, H., Chen, S., Tang, Y., Ge, R.-S., Duan, P.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2025

Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award

Sun Yat-sen University | China

AUTHOR PROFILE

Scopus

ORCID ID

🧑‍🔬 DR. SHI-LIANG HUANG

Associate Professor in Medicinal Chemistry
Sun Yat-sen University, People’s Republic of China

🎯 OBJECTIVE

Dedicated Associate Professor specializing in Medicinal Chemistry, with a passion for driving innovation in drug discovery and development, focusing on the tumor microenvironment and the heat shock response.

📘 EARLY ACADEMIC PURSUITS

Dr. Huang’s academic journey began with a solid foundation in Chemistry and Biochemistry, laying the groundwork for a distinguished career. After excelling in undergraduate studies, Dr. Huang pursued advanced degrees in Medicinal Chemistry, demonstrating exceptional aptitude for research and innovation.

Key achievements during this phase include:

  • Master’s Thesis: Groundbreaking work on natural product derivatives for therapeutic applications.
  • Doctoral Research: Advanced studies on the mechanisms of small molecules in altering biochemical pathways.

🏢 PROFESSIONAL ENDEAVORS

As an Associate Professor at Sun Yat-sen University, Dr. Huang has significantly contributed to the university’s reputation as a leading institution in medicinal research. His professional journey is marked by:

  • Leading Interdisciplinary Teams: Collaborating with experts in oncology, biochemistry, and computational modeling.
  • Research Innovation: Pioneering techniques in synthesizing inhibitors targeting heat shock proteins (HSPs) and heat shock factor 1 (HSF1).
  • Teaching Excellence: Mentoring students in natural medicinal chemistry and drug design methodologies.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Huang’s work revolves around integrating bioorganic chemistry with tumor microenvironment studies to innovate cancer therapies. Key contributions include:

  • Medicinal Chemistry: Developing novel molecules with high specificity for cancer-related targets.
  • Natural Product Exploration: Isolating and modifying natural compounds to enhance their therapeutic potential.
  • Heat Shock Response Modulation: Designing inhibitors to disrupt HSF1 and HSP pathways, which are critical in cancer cell survival under stress.
  • Tumor Microenvironment Studies: Investigating how microenvironmental factors influence drug efficacy.

🌟 IMPACT AND INFLUENCE

Dr. Huang’s research has had a profound impact on the scientific community and beyond:

  • Published Works: Author of numerous peer-reviewed articles in high-impact journals.
  • Citations and Recognition: Garnered widespread academic citations, reflecting the influence and applicability of his research.
  • Collaboration and Leadership: Actively involved in global collaborations, enhancing the translational impact of his findings.

📊 ACADEMIC CITATIONS AND METRICS

Dr. Huang’s academic metrics underscore his scholarly contributions:

  • H-Index: Demonstrates significant citation impact in medicinal chemistry and oncology.
  • Published Articles: Over 50 research papers, including breakthroughs in bioorganic and natural medicinal chemistry.
  • Research Grants: Secured funding for multiple national and international projects.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

As a visionary in drug discovery, Dr. Huang aspires to expand his research impact by:

  • Advancing precision medicine approaches tailored to the tumor microenvironment.
  • Developing next-generation inhibitors targeting stress-response proteins in cancer therapy.
  • Mentoring the next wave of researchers in innovative medicinal chemistry.

🌏 CONCLUSION

Dr. Shi-liang Huang embodies a blend of academic rigor, research innovation, and educational leadership. His contributions continue to shape the future of medicinal chemistry, with a legacy that inspires collaboration, discovery, and impactful solutions in cancer therapy.

📊🔬NOTABLE PUBLICATION:
  • A Novel HSF1 Activator Ameliorates Non-Alcoholic Steatohepatitis by Stimulating Mitochondrial Adaptive Oxidation
    • Authors: Rao, Y.; Li, C.; Hu, Y.-T.; Ye, J.-M.; Huang, Z.-S.
    • Journal: British Journal of Pharmacology
    • Year: 2022

 

  • Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex
    • Authors: Li, M.-L.; Yuan, J.-M.; Yuan, H.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
    • Authors: Pan, X.; Mao, T.-Y.; Mai, Y.-W.; Huang, Z.-S.; Huang, S.-L.
    • Journal: Molecules
    • Year: 2022

 

  • Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
    • Authors: Jiang, X.-C.; Tu, F.-H.; Wei, L.-Y.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2022

 

  • Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
    • Authors: Xu, Y.-H.; Hu, Y.-T.; Xu, S.-M.; Chen, S.-B.; Huang, Z.-S.
    • Journal: Journal of Medicinal Chemistry
    • Year: 2023

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

📚EARLY ACADEMIC PURSUITS 

ZENG QINGJUN completed his Master’s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

⚕️PROFESSIONAL ENDEAVORS 

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

🌍IMPACT AND INFLUENCE 

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

📑ACADEMIC CITATIONS 

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Dr. ZENG QINGJUN’s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

💼LEADERSHIP IN SURGICAL PRACTICE 

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

🔗 CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

📊🔬NOTABLE PUBLICATION:
  • 1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
    Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
    Journal: Cancer Biotherapy and Radiopharmaceuticals
    Year: 2023


    2. Title: Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
    Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
    Journal: Cell Biology International
    Year: 2022